News

Genetic screen not worth cost for node-negative breast cancer patients


 

FROM THE JOURNAL OF CLINICAL ONCOLOGY

References

Using a 70-gene signature screening tool for adjuvant chemotherapy decisions cost significantly more than did other methods, including giving chemotherapy to all patients, but did not confer any additional advantages in survival or quality of life, for women with node-negative breast cancer.

The estimated cost per woman with a node-negative tumor was 12,780 euros for using the MammaPrint test – significantly higher than either an online decision tool, or a strategy of systematic chemotherapy for all, according to Julia Bonastre, Ph.D., and her colleagues (J. Clin. Oncol. 2014 October [doi:10.1200/JCO.2013.54.9931]).

Molecular tests yield modest health benefits, but their high cost results in poor value for the money, according to researchers. ©Kativ/iStockphoto

Molecular tests yield modest health benefits, but their high cost results in poor value for the money, according to researchers.

The study compared cost and clinical outcomes among 307 women treated for node-negative breast cancers as part of a MammaPrint validation trial. Chemotherapy choice was guided either by MammaPrint, the Adjuvant! Online program, or a scheme of systematic chemotherapy for every patient.

The mean cost of the 70-gene MammaPrint profile was 12,780 euros; the mean cost of Adjuvant! Online, 10,743 euros; and the mean cost of systematic chemotherapy, 12,123 euros. Over the 10-year follow-up period, there were no differences in life-years or quality-adjusted life-years.

Treatment de-escalation is critical for ensuring high-quality survivorship over the long term, wrote Dr. Bonastre of Gustave Roussy Institute of Oncology, Paris, and her associates. “However, our study shows that the health benefits associated with the use of molecular tests are modest. In addition, the high price of these tests results in poor value for the money, limiting their usefulness in routine practice,” they said.

The study was funded by the French National Cancer Institute, and the authors reported no conflicts of interest.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Recommended Reading

Survival benefit from contralateral prophylactic mastectomy small
MDedge Family Medicine
Early results show promise of topical tamoxifen for women with DCIS
MDedge Family Medicine
Early results show promise of topical tamoxifen for women with DCIS
MDedge Family Medicine
Recent use of oral contraceptives linked to breast cancer
MDedge Family Medicine
Bisphosphonates don’t cut risk of breast cancer
MDedge Family Medicine
No rise in breast cancer recurrence found with TNF inhibitor use
MDedge Family Medicine
Researchers deem tumor-infiltrating lymphocytes valid prognostic biomarker in TNBC
MDedge Family Medicine
VIDEO: Breast cancer symposium take-home messages, Day 1
MDedge Family Medicine
VIDEO: Unclear if altering lifestyle affects breast cancer
MDedge Family Medicine
AUDIO: Hope Rugo reviews pivotal breast cancer trials at ESMO
MDedge Family Medicine